Seven year €185 million project. Thirty partners from 13 countries to deliver an efficient global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards. The goal is to deliver 2 novel phase 2 clinical trials to accelerate the development of new anti-tuberculosis drugs and regimens. The UStAn group plays a key role in Work package 7 to develop definitions for biomarkers to monitor treatment effectiveness.
Tuberculosis (TB) Trials
